



中西整合醫學會

會訊

Taiwan Society for Integration of Chinese and Western Medicine

◎ 發行所: 中西整合醫學會

◎ 內政部台內社字第8209883號

◎ 創刊日期: 2006年3月29日

◎ 發行日期: 2025年8月29日

◎ 總編輯: 傅彬貴、梁信杰、蕭望德

◎ 執行編輯: 陳映儀

◎ 劃撥帳號: 21511322

◎ 網址: <http://www.cwm.org.tw>

◎ Email: society.cwm@gmail.com

◎ 電話: 04-2205-3366 #3119

◎ 傳真: 04-2207-7140

◎ 地址: 404328 台中市北區學士路91號

◎ 臺灣中西整合醫學會理事長: 張恒鴻

◎ 臺灣中西整合消化醫學會理事長: 賴學洲

◎ 中西整合癌症醫學會理事長: 高尚德

2025年8月出刊 VOL.117

慢性阻塞性肺病大師課程 Lesson 2

Optimal Treatment for COPD symposium

9/17
(WED)

12:30~13:30



線上視訊

| Time | Topic | Speaker | Moderator |
|-------------|--|-------------------|------------------|
| 12:30-12:40 | Opening Remarks | 陳崇裕 主任 雲林臺大醫院 | |
| 12:40-13:20 | Beyond Eosinophils: Revisiting the Paradigm of Airway Immunity in COPD | 傅彬貴 教授 台中榮民總醫院 | 陳崇裕 主任 雲林臺大醫院 |
| 13:20-13:30 | Panel Discussion | 陳崇裕 主任 雲林臺大醫院 | |

主辦單位:



臺灣中西整合醫學會
Taiwan Society for Integration of
Chinese and Western Medicine

協辦單位:



台灣分級醫療學會
Taiwan Association of Promoting Care Continuity (TAPCC)

👉 報名連結: <https://forms.gle/DfVaBo3wQKE8vQB6>

本次申請學分: 內科醫學會、台灣胸腔暨重症加護醫學會

主題: Beyond Eosinophils: Revisiting the Paradigm of Airway Immunity in COPD

突破嗜酸性球框架: 重新詮釋COPD的氣道免疫機制

講師: 傅彬貴 教授 (台中榮民總醫院)

座長: 陳崇裕 主任 (雲林臺大醫院)



慢性阻塞性肺病大師課程 Lesson 3 Optimal Treatment for COPD symposium

10/15

(WED)

12:30~13:30

| Time | Topic | Speaker | Moderator |
|-------------|--|----------------------|-------------------|
| 12:30-12:40 | Opening Remarks | 傅彬貴 秘書長 臺灣中西整合醫學會 | |
| 12:40-13:20 | Type 2 Airway Disease in 2025 ERS: Latest Insights from Asthma and COPD | 羅柏鈞 醫師 衛福部桃園醫院 | 傅彬貴 教授 臺中榮民總醫院 |
| 13:20-13:30 | Panel Discussion | 傅彬貴 教授 臺中榮民總醫院 | |

主辦單位:



臺灣中西整合醫學會
Taiwan Society for Integration of
Chinese and Western Medicine

協辦單位:



台灣分級醫療學會
Taiwan Association of Promoting Core Competency (TAPCC)

👉 報名連結: <https://forms.gle/NPkHsE75raCV8Xz2A>

本次申請學分: 內科醫學會、台灣胸腔暨重症加護醫學會

主題: Type 2 Airway Disease in 2025 ERS: Latest Insights from Asthma and COPD

2025年ERS大會新知update: 聚焦氣喘與COPD的第二型發炎反應

講師: 羅柏鈞 醫師 (衛福部桃園醫院)

座長: 傅彬貴 教授 (台中榮民總醫院)



「中西醫聯合疾病研討會」活動報導

2025年7月27日（星期日）上午，本會舉辦的「中西醫聯合疾病研討會」透過 Cisco Webex 線上舉行，吸引來自全台各地的醫療專業人士熱情參與。第一場由國立臺灣大學醫學院附設醫院耳鼻喉部林怡岑醫師主講，臺中榮民總醫院傅彬貴教授擔任座長，深入探討過敏性鼻炎與鼻息肉的診斷流程及治療策略，從藥物、免疫治療到手術應用皆有精闢分享。第二場由中國醫藥大學附設醫院高齡醫學科林志學主任主講，彰化基督教醫院杜思德醫師擔任座長，分析肺炎鏈球菌疾病在成年人，特別是高齡族群中的疾病負擔與防治重點，並強調疫苗接種的重要性。與會醫師踴躍發問、分享經驗，討論氣氛熱絡，充分展現跨領域交流的價值。短短兩個半小時的會議內容專業充實，跨專科交流不僅拓展臨床視野，也為病患帶來更多元的照護選擇。



林怡岑

國立臺灣大學醫學院附設醫院
耳鼻喉部



林志學

中國醫藥大學附設醫院
社區暨家庭醫學部
高齡醫學科



傅彬貴

臺中榮民總醫院
醫學研究部臨床試驗科



杜思德

彰化基督教醫院
新陳代謝科



Immunomodulatory and anti-inflammatory properties of dictamnine-free phytopharmaceuticals from Dictamni Cortex with phototoxicity evaluation

Chia-Lin Lee ^{a b c}, Chien-Ming Wang ^c, Si-Min Lu ^a, Ying-Chyi Song ^{c d}, Hsiu-Mei Chiang ^a, Hsiao-Fang Liao ^e, Hung-Rong Yen ^{c f g h}

^aDepartment of Cosmeceutics, China Medical University, Taichung, 40604, Taiwan

^bChinese Medicine Research and Development Center, China Medical University Hospital, Taichung, 40447, Taiwan

^cChinese Medicine Research Center, China Medical University, Taichung, 40402, Taiwan

^dGraduate Institute of Integrated Medicine, China Medical University, Taichung, 40402, Taiwan

^ePh.D. Program for Biotechnology Industry, China Medical University, Taichung, 40604, Taiwan

^fResearch Center for Traditional Chinese Medicine, China Medical University Hospital, Taichung, 40447, Taiwan

^gDepartment of Chinese Medicine, China Medical University Hospital, Taichung, 40447, Taiwan

^hSchool of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan

Journal of Ethnopharmacology Volume 352, 29 August 2025, 120268

<https://doi.org/10.1016/j.jep.2025.120268>

Impact factor:5.4

Abstract

Ethnopharmacological relevance

Dictamni Cortex (*Dictamnus dasycarpus* root barks) has been widely applied across Asia for inflammatory dermatological conditions, including eczema, pruritus, allergies, and urticaria. Among the active compounds in Dictamni Cortex, dictamnine exhibits notable anti-inflammatory and antipruritic properties, contributing to its therapeutic effects against skin inflammation. However, dictamnine, a furoquinoline alkaloid, shares a structural framework with linear furanocoumarines such as 8-methoxypsoralen and 5-methoxypsoralen, which are known for their photoactive properties. Similar to psoralens, dictamnine also demonstrates phototoxic characteristics.

Aim of the study

This research focused on developing safer plant-based medicines derived from Dictamni Cortex by formulating extracts devoid of dictamnine analogues (DDE-A1 and DDE-B1) and evaluating their potential as novel therapeutic agents. The investigation focused on their immunomodulatory and anti-inflammatory effects, as well as their phototoxicities. Correspondingly, alkaloid-rich fractions containing dictamnine (DDE-A2 and DDE-B2) were also prepared to compare their phototoxic effects.

Materials and methods

To isolate pure compounds from the potential fraction (DDE) of Dictamni Cortex, column chromatography was performed using silica, C18-reversed phase silica gels, and gel filtration resin as stationary phases. Two novel DDE formulations free from dictamnine alkaloids (DDE-A1 and DDE-B1) were obtained using acid-base extraction and acidic resin (Dowex® 50WX4 hydrogen form) column separation methods. Immunomodulatory effects were assessed using Th17/IL-17 and Th2/IL-4 cell models, while anti-inflammatory effects were evaluated by analyzing TNF- α - or IL-17A-induced IL-6 and IL-8 levels in HaCaT cells. Phototoxicity was tested in HaCaT cells with and without UV exposure.

Results

Two novel DDE formulations lacking dictamnine alkaloids (DDE-A1 and DDE-B1) were successfully prepared by aforementioned two methods, respectively. Experimental results indicated that DDE-A1 and DDE-B1 exhibited no phototoxicity while retaining immunomodulatory and anti-inflammatory potential. Conversely, the dictamnine alkaloid-rich fractions (DDE-A2 and DDE-B2) showed significant phototoxicity, exceeding the toxicity of dictamnine alone. These findings suggest that DDE-A1 and DDE-B1 as promising candidates for safe and effective therapeutic agents for dermatitis.

Conclusions

This pilot study successfully developed detoxified and bioactive phytopharmaceuticals (DDE-A1 and DDE-B1) and photosensitive dictamnine-rich alkaloid formulations (DDE-A2 and DDE-B2) from Dictamni Cortex. The DDE-A1 and DDE-B1 formulations demonstrated robust immunomodulatory and anti-inflammatory effects without phototoxicity, paving the way for the development of safer, plant-based dermatological drugs.